Trial Profile
(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs PAC 1 (Primary)
- Indications Haematological malignancies; Lymphoma; Neuroendocrine tumours; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms Component 1
- Sponsors Vanquish Oncology
- 05 Dec 2022 Results published in the British Journal of Cancer
- 22 Sep 2020 Status changed from recruiting to completed.
- 03 Apr 2019 Results of STM-03 of component 1 (n=44) and component-2 (n=12) study presented at the 110th Annual Meeting of the American Association for Cancer Research.